Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study

REFERENCES

• Einhorn EH: Testicular cancer: An oncological success story. Clin Cancer Res, 1997; 3: 2630–2632.
   Google Scholar
• Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435–40.
   PubMed Web of Science ®Google Scholar
• Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S et al. A. Prognostic factors for favorable outcome in dissemi-nated germ cell tumors. J Clin Oncol 1986; 4: 400–7.
   Google Scholar
• Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G et al. Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: an SECSG protocol. J Clin Oncol 1989; 7: 387–91.
   Google Scholar
• Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. The importance of bleomycin in favorable prognosis dissemi-nated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13: 470–6.
   PubMed Web of Science ®Google Scholar
• Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 2006; 4 (10): 1059–70.
   PubMedGoogle Scholar
• van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Boldcel Huinink WW, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24 (3): 467–75.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Aass N, Fossá SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18 (2): 241–8.
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicu-lar cancer. J Clin Oncol 2005; 23 (16): 3718–25.
   PubMed Web of Science ®Google Scholar
• Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fossa SD. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 2007; 52 (5): 1438–47.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in tes-ticular cancer survivors. J Clin Oncol 2007; 25 (6): 708–14.
   PubMed Web of Science ®Google Scholar
• Kawai K, Akaza H. Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. Expert Opin Drug Safety 2003; 2 (6): 587–96.
   PubMedGoogle Scholar
• van Barneveld PW, Sleijfer DT, van der Mark TW, Mulder NH, Donker AJ, Meijer S, et al Influence of platinum-induced renal toxicity on bleomycin-induced pulmonary toxicity in Patients with disseminated testicular carcinoma. Oncology 1984; 41 (1): 4–7.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from in-complete observations. J Am Stat Assoc 1958; 53: 457–81.
   Web of Science ®Google Scholar
• Simon R. Confidence interval for reporting results of clin-ical trials. Ann Intern Med 1986; 105 (3): 429–435.
   PubMed Web of Science ®Google Scholar
• International Germ Cell Cancer Collaborative Group (IGC-CCG). The International Germ Cell Consensus Clasification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 1997; 15: 594–603.
   Google Scholar
• Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Gol-bey RB, et al. A randomized trial of etoposide +cisplatin versus vinblastine + bleomycin + cisplatin + cyclophoshamide + dactin-omycin in patients with god prognosis germ cell tumors. J Clin Oncol 1988; 6 (8): 1231–8.
   PubMed Web of Science ®Google Scholar
• Levi JA, Raghavan D, Harvey V, Thompson D, Sande-man T, Gill G, et al. The importance of bleomycin in combina-tion chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 1993; 11 (7): 1300–5.
   PubMed Web of Science ®Google Scholar
• Stoter G, Kaye S, Sleyfer D, et al: Preliminary results of BEP (bleomycin, etoposide, cisplatin) versus EP in low volume metastatic (LVM) testicular non-seminomas. An EORTC study. Proc Am Soc Clin Oncol 1987; 6:110, (abstr).
   Google Scholar
• Gerson R, Tellez Bernal E, Lazaro Leon M, Sanchez For-gach E, Garcia Irigoyen C, Gutierrez Godinez F, et al. Low toxi-city with continuous infusion of high-dose bleomycin in poor prognostic testicular cancer. Am J Clin Oncol 1993; 16 (4): 323–6.
   PubMed Web of Science ®Google Scholar
• Remick SC, Reddy M, Herman D, Grace C, Harper G, Willis K, et al. Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma J Clin Oncol 1994; 1130-1136.
   Google Scholar
• de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW et al. Importance of bleomycin in combina-tion chemotherapy for good-prognosis testicular non seminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Coopera-tive Group. J Clin Oncol 1997; 15 (5): 1837–43.
   Google Scholar
• Manavis J, Ambatzoglou J, Sismanidou K, Koukourakis MI. Computed tomography scan evaluation of late toxicity fol-lowing hypofractionated/accelerated radiotherapy with cytopro-tection in breast cancer treated with conservative surgery. Am J Clin Oncol 2006; 29 (5): 478–83.
   Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Bajorin D, Dobrzynski D, She-infeld J, Motzer RJ et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005; 23 (36): 9290–4.
   Google Scholar
• Perry DJ, Weiss RB, Taylor HG. Enhanced bleomycin tox-icity during acute renal failure. Cancer Treat Rep 1982; 66: 592–93.
   PubMedGoogle Scholar
• Bennett WM, Pastore L, Houghton DC. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep 1980; 64: 921–24.
   PubMedGoogle Scholar
• Fos SD, de Wit R, Roberts JT, Wilkinson PM, de Mul-der PH, Mead GM et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the Eu-ropean Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Can-cer Study Group (30941/TE20). J Clin Oncol 2003; 21: 1107–18.
   Google Scholar
• Waid-Jones MI, Coursin DB. Perioperative considerations for patients treated with bleomycin. Chest 1991; 99: 993–9.
   PubMed Web of Science ®Google Scholar
• Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Al-gaba F et al. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meet-ing of the European Germ Cell Cancer Consensus Group (EGC-CCG): Part II. Eur Urol 2008; 53: 497–513.
   Google Scholar